Business Wire

GE Healthcare: DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging Demonstrates Impact on the Diagnosis and Clinical Management of Patients with Clinically Uncertain ...

NEW ORLEANS, La.-- (BUSINESS WIRE)--GE Healthcare today presented the results of a randomized study analyzing the effect of DaTscan™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult ...
Medscape

New Contrast Agent Enables Earlier Diagnosis in Parkinson's

VANCOUVER, British Columbia — When the contrast agent ioflupane with iodine-123 (DaTscan, GE Healthcare) is used with single-photon emission computed tomography ...
Nasdaq

GE Healthcare Announces First Patient Dosed in Phase III Clinical Trial for New Dopamine Transporter Imaging Radiopharmaceutical

First patient dosed in Phase III clinical trial for PET radiopharmaceutical Next stage clinical study also proceeding for SPECT radiopharmaceutical Both imaging agents aim to assist in the evaluation ...
Medscape

Parkinson's Imaging Agent Descheduled

The imaging agent, ioflupane I 123 (DaTscan; GE Healthcare), has been removed from the schedules of the US Controlled Substances Act, meaning that it will be more widely available for use in the ...
The Globe and Mail

DATSCAN™ (Ioflupane I 123 Injection) indication expanded to include use in patients with suspected Dementia with Lewy Bodies (DLB)

GE Healthcare’s DaTscan has been approved by the U.S. Food and Drug Administration (FDA) for use in patients with suspected Dementia with Lewy Bodies (DLB). This new indication is in addition to its ...
Monthly Prescribing Reference

DaTscan Available to Assess Parkinsonian Syndromes

GE Healthcare announced that DaTscan (Ioflupane I 123 Injection) is available for the detection of dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes.
Monthly Prescribing Reference

DaTscan radiopharmaceutical agent approved for detection of dopamine transporters

The FDA has approved DaTscan (Ioflupane I 123 Injection, from GE Healthcare) for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) ...
Nasdaq

GE Healthcare Announces FDA Approval For Use Of DaTscan In Suspected Dementia With Lewy Bodies

(RTTNews) - GE Healthcare (GE) announced on Thursday that DaTscan was approved by FDA for use in patients with suspected Dementia with Lewy Bodies or DLB. DaTscan is a radiopharmaceutical imaging ...
pix11

SimonMed Announces offering of DaTscan

SCOTTSDALE, Ariz., April 24, 2023 /PRNewswire/ -- SimonMed is proud to announce we will offer GE HealthCare's radiopharmaceutical diagnostic tracer, DaTscan™ (Ioflupane I 123 injection), with ...
The American Journal of Managed Care

Effective and Efficient Diagnosis of Parkinsonism: The Role of Dopamine Transporter SPECT Imaging With Ioflupane I-123 Injection (DaTscanâ„¢)

Parkinson’s disease (PD), the second-most common neurodegenerative disease, is characterized by motor and nonmotor symptoms. PD is often misdiagnosed; inappropriate treatment due to misdiagnosis has ...
Stockhouse

DATSCAN(TM) (Ioflupane I 123 Injection) indication expanded to include use in patients with suspected Dementia with Lewy Bodies (DLB)

DaTscan is first radiopharmaceutical diagnostic tracer approved by U.S. FDA for use in patients with suspected Dementia with Lewy Bodies (DLB) Builds on DaTscan market leadership globally with over ...